menu
    • menu

    Company profile for PEP-Therapy

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms...
    PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PEP-TherapyFrance Flag
    Country
    Country
    France
    Address
    Address
    Pépinière Paris Santé Cochin 29 rue du Faubourg Saint Jacques 75014 Paris
    Telephone
    Telephone
    +33 1 81 70 76 82
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pep-therapy.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PEP-Therapy gets Orphan Drug Designation for Pancreatic Cancer
    PEP-Therapy gets Orphan Drug Designation for Pancreatic Cancer

    17 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/17/3043732/0/en/PEP-Therapy-receives-FDA-Orphan-Drug-Designation-for-PEP-010-for-treatment-of-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    17 Mar 2025
    Share Share
    PEP-Therapy, Curie: First Patients Dosed With PEP-010 in Ovarian
    PEP-Therapy, Curie: First Patients Dosed With PEP-010 in Ovarian

    25 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/25/2869379/0/en/PEP-Therapy-and-Institut-Curie-Announce-First-Patients-Dosed-in-Phase-Ib-Clinical-Trial-Evaluating-PEP-010-in-Ovarian-and-Pancreatic-Cancers.html

    GLOBENEWSWIRE
    25 Apr 2024
    Share Share
    PEP-Therapy, Institut Curie begins patient dosing in phase I trial of PEP-010
    PEP-Therapy, Institut Curie begins patient dosing in phase I trial of PEP-010

    06 Oct 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=143056&sid=2

    PHARMABIZ
    06 Oct 2021
    Share Share
    PEP-Therapy extends Series-A financing
    PEP-Therapy extends Series-A financing

    19 Jul 2021

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pep-therapy-extends-series-a-financing-raising-a-total-of-5-4-million-to-progress-the-clinical-development-of-its-lead-candidate-pep-010--301335760.html

    PR NEWSWIRE
    19 Jul 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search